<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200213">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483899</url>
  </required_header>
  <id_info>
    <org_study_id>SIG102335</org_study_id>
    <nct_id>NCT00483899</nct_id>
  </id_info>
  <brief_title>Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects</brief_title>
  <official_title>Double-blind, Placebo-controlled, 3-way Crossover Study to Investigate the Effect of 7-days Repeat Once Daily Inhaled Doses of GW870086X Administered Via DISKHALER on Airway Responsiveness to AMP in Mild Steroid-naive Male Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to look at safety aspects and effects of repeat inhaled doses of
      GW870086X in mild asthmatics to develop this drug for its use in asthma and chronic
      obstructive pulmonary disease (COPD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lung function 2 hours after treatment on day 7</measure>
    <time_frame>on day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lung function 14 and 26 hours after treatment on day 7; Change in lung function 2 hours after treatment on day 1; Effects on blood and urine tests; effects on the heart, pulse rate and blood pressure; effects on the lungs</measure>
    <time_frame>2 hours after treatment on day 1, 14 and 26 hours after treatment on day 7;</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW870086X</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male subjects aged 18-55

          -  Documented history of bronchial asthma diagnosed at least 6 months ago.

          -  Only being treated with short-acting beta-2-agonist therapy e.g. Ventolin

          -  Documented sensitivity to adenosine mono phosphate (AMP) at screening visit

          -  Demonstrate repeatable and reproducable response to inhaled AMP at the run-in visit

        Exclusion criteria:

          -  Any significant illness or disease

          -  History of life threatening asthma

          -  History of respiratory tract infection

          -  Subjects who take medication for their asthma, or other conditions, not compatible
             with this study.

          -  Smoker

          -  Subjects who are oversensitive to corticosteroids

          -  History of drug or alcohol abuse

          -  Donated blood within last 3 months

          -  Been involved in another clinical trial during the last 3 months

          -  Subjects who work night shifts

          -  Subjects who are undergoing de-sensitisation therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>May 31, 2012</lastchanged_date>
  <firstreceived_date>June 5, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW870086X Asthma Crossover repeat dose inhaled</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
